

Title: UM-MP353 Keytruda (pembrolizumab)	Division: Medical Management Department: Utilization Management
Approval Date: 7/22/2025	LOB: QHP, Gold, Goldcare
Effective Date: 7/22/2025	Policy Number: UM-MP353
Review Date: 7/22/2026	Cross Reference Number:
Retired Date:	Page 1 of 23

1. POLICY DESCRIPTION:

Antineoplastic Agent, Anti-PD-2 Monoclonal Antibody; Antineoplastic Agent, Immune Checkpoint Inhibitor – Keytruda (pembrolizumab)

2. RESPONSIBLE PARTIES:

Medical Management Administration, Pharmacy Department, Utilization Management, Integrated Care Management, Claims Department

3. DEFINITIONS:

Keytruda is a monoclonal antibody that acts as an immune checkpoint inhibitor by binding to the human programmed death-1 (PD-1) receptor on T cells and blocking the PD-1 interaction with PD-1 ligands (L1, L2) which allows activated tumor-specific T cells to kill tumor cells and secrete cytokines to restore antitumor immune responses.

Abbreviation	Description
PD-1	human programmed death-1
NSCLC	Non-small Cell Lung Cancer
eGFR	estimated glomerular filtration rate
ALK	anaplastic lymphoma kinase
MPM	Malignant Pleural Mesothelioma
HNSCC	Head and Neck Squamous Cell Cancer
CPS	Combined Positive Score
cHL	Classical Hodgkin Lymphoma
PMBCL	Primary Mediastinal Large B-Cell Lymphoma
BCG	Bacillus Calmette-Guerin
NMIBC	high-risk, non-muscle invasive bladder cancer
CIS	carcinoma in situ
MSI-H	metastatic microsatellite instability-high
dMMR	mismatch repair deficient
CRC	colorectal cancer
GEJ	gastroesophageal junction
HCC	Hepatocellular Carcinoma
BTC	Biliary Tract Cancer
MCC	Merkel Cell Carcinoma
RCC	Renal Cell Carcinoma
pMMR	Mismatch repair proficient
TMB-H	Tumor Mutational Burden-High



Title: UM-MP353 Keytruda (pembrolizumab)	Division: Medical Management Department: Utilization Management
Approval Date: 7/22/2025	LOB: QHP, Gold, Goldcare
Effective Date: 7/22/2025	Policy Number: UM-MP353
Review Date: 7/22/2026	Cross Reference Number:
Retired Date:	Page 2 of 23

CSCC	Cutaneous Squamous Cell Carcinoma
TNBC	triple-negative breast cancer

4. POLICY:

Keytruda will be considered medically necessary once the following coverage criteria is met. Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines.

Chart notes must be submitted to confirm diagnosis and previous treatment(s).

INITIAL REQUEST:

1. Melanoma

A. Treatment of melanoma in ONE of the following settings:

- i. For unresectable or metastatic disease as a single agent;

OR

- ii. ALL of the following:

- 1. Patient is ≥ 12 years of age;

AND

- 2. Prescribed as adjuvant treatment in patients with stage IIB, IIC, or III melanoma following complete resection;

AND

- B. Authorization is for no more than 6 months

2. Non-small Cell Lung Cancer (NSCLC)

A. ONE of the following:

- i. Keytruda will be used in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no estimated glomerular filtration rate (eGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations;

OR

- ii. Keytruda will be used in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, as first-line treatment of patients with metastatic squamous NSCLC;

OR

- iii. Keytruda will be used as first-line monotherapy in stage III patients with NSCLC whose tumors test positive for PD-L1 expression (Tumor Proportion Score [TPS] $\geq 1\%$ using an FDA-approved test), and patient lacks EGFR or

Title: UM-MP353 Keytruda (pembrolizumab)	Division: Medical Management Department: Utilization Management
Approval Date: 7/22/2025	LOB: QHP, Gold, Goldcare
Effective Date: 7/22/2025	Policy Number: UM-MP353
Review Date: 7/22/2026	Cross Reference Number:
Retired Date:	Page 2 of 23

ALK mutations who are not candidates for surgical resection or definitive chemoradiation, or metastatic;

OR

- iv. Keytruda will be used as a single agent as subsequent treatment if PD-L1 $\geq 1\%$ in metastatic disease with disease progression on or after platinum-containing chemotherapy (Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving Keytruda);

OR

- v. Keytruda will be used for the treatment of patients with resectable (tumors ≥ 4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery;

OR

- vi. Keytruda will be used as a single agent for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥ 4 cm), II, or IIIA NSCLC;

AND

- B. Authorization is for no more than 6 months

3. Malignant Pleural Mesothelioma (MPM)

- A. Adult patients with unresectable advanced or metastatic MPM;

AND

- B. Will be used as a first-line treatment in combination with pemetrexed and platinum chemotherapy;

AND

- C. Authorization is for no more than 6 months

4. Head and Neck Squamous Cell Cancer (HNSCC)

- A. ONE of the following:

- i. Keytruda will be used as a single agent for first-line treatment in patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 (Combined Positive Score (CPS ≥ 1) as determined by an FDA-approved test;

OR

- ii. Keytruda will be used in combination with platinum and fluorouracil for first-line treatment of metastatic or with unresectable, recurrent HNSCC;

OR

Title: UM-MP353 Keytruda (pembrolizumab)	Division: Medical Management Department: Utilization Management
Approval Date: 7/22/2025	LOB: QHP, Gold, Goldcare
Effective Date: 7/22/2025	Policy Number: UM-MP353
Review Date: 7/22/2026	Cross Reference Number:
Retired Date:	Page 2 of 23

- iii. Keytruda will be used as a single agent for patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy (regardless of PD-L1 status);

AND

- B. Authorization is for no more than 6 months

5. Classical Hodgkin Lymphoma (cHL)

- A. ONE of the following:

- i. For the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma as a single agent;

OR

- ii. Treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more prior lines of therapy;

AND

- B. Authorization is for no more than 6 months

6. Primary Mediastinal Large B-Cell Lymphoma (PMBCL)

- A. Treatment of primary mediastinal large B-cell lymphoma in patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy;

AND

- B. Authorization is for no more than 6 months

7. Urothelial Carcinoma

- A. ONE of the following:

- i. Keytruda will be used in combination with enfortumab vedotin, for the treatment of adult patients with locally advanced or metastatic urothelial cancer;

OR

- ii. Keytruda will be used as a single agent for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have ONE of the following:

- 1. Patient is not eligible for any platinum-containing chemotherapy;

OR

- 2. Patient has disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy;

OR

- iii. Keytruda is used as a single agent for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle

Title: UM-MP353 Keytruda (pembrolizumab)	Division: Medical Management Department: Utilization Management
Approval Date: 7/22/2025	LOB: QHP, Gold, Goldcare
Effective Date: 7/22/2025	Policy Number: UM-MP353
Review Date: 7/22/2026	Cross Reference Number:
Retired Date:	Page 2 of 23

invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy;

AND

B. Authorization is for no more than 6 months

8. Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient Cancer (dMMR)

A. Keytruda will be used in adult and pediatric patients for the treatment of unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA approved test;

AND

B. Have no satisfactory alternative treatment options;

AND

C. Authorization is for no more than 6 months

9. Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer (CRC)

A. Patient has diagnosis of microsatellite instability-high or mismatch repair deficient colorectal cancer (CRC) as determined by an FDA-approved test;

AND

B. Authorization is for no more than 6 months

10. Gastric Cancer

A. ONE of the following:

i. Keytruda will be given in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS \geq 1) as determined by an FDA-approved test;

OR

ii. Keytruda will be given in combination with fluoropyrimidine and a platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma;

AND

B. Authorization is for no more than 6 months

Title: UM-MP353 Keytruda (pembrolizumab)	Division: Medical Management Department: Utilization Management
Approval Date: 7/22/2025	LOB: QHP, Gold, Goldcare
Effective Date: 7/22/2025	Policy Number: UM-MP353
Review Date: 7/22/2026	Cross Reference Number:
Retired Date:	Page 2 of 23

11. Esophageal Cancer

- A. Keytruda will be used for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation with ONE of the following:
 - i. Used in combination with platinum- and fluoropyrimidine-based chemotherapy;
 - OR**
 - ii. Used as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS ≥ 10) as determined by an FDA-approved test;

AND

- C. Authorization is for no more than 6 months

12. Cervical Cancer

- A. Used for the treatment of cervical cancer in ONE of the following settings:
 - i. Keytruda will be used in combination with chemoradiotherapy, for the treatment of patients with FIGO 2014 Stage III-IVA cervical cancer;
 - OR**
 - ii. Keytruda will be used in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥ 1) as determined by an FDA-approved test;
 - OR**
 - iii. Keytruda will be used as a single agent for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumor express PD-L1 (CPS ≥ 1) as determined by an FDA-approved test;

AND

- B. Authorization is for no more than 6 months

13. Hepatocellular Carcinoma (HCC)

- A. Treatment of patients with hepatocellular carcinoma secondary to hepatitis B who have previously received systemic therapy other than PD-1/PD-L1 containing regimen;

AND

- B. Authorization is for no more than 6 months

Title: UM-MP353 Keytruda (pembrolizumab)	Division: Medical Management Department: Utilization Management
Approval Date: 7/22/2025	LOB: QHP, Gold, Goldcare
Effective Date: 7/22/2025	Policy Number: UM-MP353
Review Date: 7/22/2026	Cross Reference Number:
Retired Date:	Page 2 of 23

14. Biliary Tract Cancer (BTC)

- A. Keytruda will be used in combination with gemcitabine and cisplatin, for the treatment of patients with locally advanced, unresectable or metastatic biliary tract cancer;

AND

- B. Authorization is for no more than 6 months

15. Merkel Cell Carcinoma (MCC)

- A. Keytruda will be used in adult and pediatric patients for the treatment of recurrent, locally advanced, or metastatic Merkel cell carcinoma;

AND

- B. Authorization is for no more than 6 months

16. Renal Cell Carcinoma (RCC)

- A. Treatment of renal cell carcinoma, when ONE of the following criteria is met:

- i. Keytruda will be used in adult patients as first-line treatment in combination with axitinib or lenvatinib for advanced Renal Cell Carcinoma;

OR

- ii. Keytruda will be used for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions;

AND

- B. Authorization is for no more than 6 months

17. Endometrial Carcinoma

- A. Used in combination with carboplatin and paclitaxel for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma;

OR

- B. Used in combination with lenvatinib, for the treatment of adult patients with advanced endometrial carcinoma, and has ALL of the following:

- i. Mismatch repair proficient (pMMR) or not MSI-H endometrial carcinoma as determined by and FDA-approved test;

AND

- ii. Disease progression following prior systemic therapy in any setting;

AND

- iii. Are not candidates for curative surgery or radiation;

OR

Title: UM-MP353 Keytruda (pembrolizumab)	Division: Medical Management Department: Utilization Management
Approval Date: 7/22/2025	LOB: QHP, Gold, Goldcare
Effective Date: 7/22/2025	Policy Number: UM-MP353
Review Date: 7/22/2026	Cross Reference Number:
Retired Date:	Page 2 of 23

- C. Used as a single agent for the treatment of adult patients with advanced endometrial carcinoma and ALL of the following:
 - i. MSI-H or dMMR endometrial carcinoma as determined by an FDA-approved test;
 - AND**
 - ii. Disease progression following prior systemic therapy in any setting;
 - AND**
 - iii. Are not candidates for curative surgery or radiation;
- AND**
- D. Authorization is for no more than 6 months

18. Tumor Mutational Burden-High (TMB-H) Cancer

- A. For the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥ 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA approved test, that have progressed following prior treatment;
- AND**
- B. Patient has no satisfactory alternative treatment options;
- AND**
- C. Authorization is for no more than 6 months

19. Cutaneous Squamous Cell Carcinoma (cSCC)

- A. ONE of the following:
 - i. Treatment of recurrent or metastatic cutaneous squamous cell carcinoma;
 - OR**
 - ii. Treatment of locally advanced cutaneous squamous cell carcinoma that is not curable by surgery or radiation;
- AND**
- B. Authorization is for no more than 6 months

20. Triple-Negative Breast Cancer (TNBC)

- A. ONE of the following:
 - i. Treatment of locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) when BOTH of the following criteria are met:
 - 1. Tumor must express PD-L1 (CPS ≥ 10) as determined by an FDA approved test;
 - AND**

Title: UM-MP353 Keytruda (pembrolizumab)	Division: Medical Management Department: Utilization Management
Approval Date: 7/22/2025	LOB: QHP, Gold, Goldcare
Effective Date: 7/22/2025	Policy Number: UM-MP353
Review Date: 7/22/2026	Cross Reference Number:
Retired Date:	Page 2 of 23

2. The requested medication will be used in combination with chemotherapy;

OR

- ii. Treatment of high-risk-early-stage-triple-negative breast cancer (TNBC) when BOTH of the following criteria are met:

1. Used in combination with chemotherapy as neoadjuvant treatment;

AND

2. Continued as a single agent as adjuvant treatment after surgery;

AND

- B. Authorization is for no more than 6 months

RENEWAL REQUEST

1. Adjunct Treatment of Melanoma or High-risk Early-Stage TNBC

- A. Continuation of treatment in patients requesting reauthorization for cutaneous melanoma or high-risk early-stage TNBC who have not experienced disease recurrence or an unacceptable toxicity;

AND

- B. Authorization is for no more than 6 months (up to 12 months total)

2. NSCLC, HNSCC, cHL, PMBCL, MSI-H or dMMR Cancers, Gastric Cancer, Esophageal Cancer, Cervical Cancer, HCC, MCC, RCC, Endometrial carcinoma, cSCC, locally recurrent unresectable or metastatic TNBC, TMB-H Cancer

- A. Continuation of treatment in patients requesting reauthorization for NSCLC, HNSCC, cHL, PMBCL, MSI-H or dMMR cancers, gastric cancer, esophageal cancer, cervical cancer, HCC, MCC, RCC, endometrial carcinoma, cSCC, locally recurrent unresectable or metastatic TNBC, and TMB-H cancers who have not experienced disease progression or unacceptable toxicity;

AND

- B. Authorization is for no more than 6 months (up to 24 months for continuous use)

3. All Other Indications

- A. Continuation of treatment in patients requesting reauthorization for an indication listed in the previous section who have not experienced disease progression or an unacceptable toxicity;

AND

- B. Authorization is for no more than 6 months

Title: UM-MP353 Keytruda (pembrolizumab)	Division: Medical Management Department: Utilization Management
Approval Date: 7/22/2025	LOB: QHP, Gold, Goldcare
Effective Date: 7/22/2025	Policy Number: UM-MP353
Review Date: 7/22/2026	Cross Reference Number:
Retired Date:	Page 2 of 23

5. APPLICABLE PROCEDURE CODES:

CPT	Description
J9271	Injection, pembrolizumab, 1 mg

6. APPLICABLE DIAGNOSIS CODES:

CODE	
C00.0	Malignant neoplasm of external upper lip
C00.1	Malignant neoplasm of external lower lip
C00.2	Malignant neoplasm of external lip, unspecified
C00.3	Malignant neoplasm of upper lip, inner aspect
C00.4	Malignant neoplasm of lower lip, inner aspect
C00.5	Malignant neoplasm of lip, unspecified, inner aspect
C00.6	Malignant neoplasm of commissure of lip, unspecified
C00.8	Malignant neoplasm of overlapping sites of lip
C00.9	Malignant neoplasm of lip, unspecified
C01	Malignant neoplasm of base of tongue
C02.0	Malignant neoplasm of dorsal surface of tongue
C02.1	Malignant neoplasm of border of tongue
C02.2	Malignant neoplasm of ventral surface of tongue
C02.3	Malignant neoplasm of anterior two-thirds of tongue, part unspecified
C02.4	Malignant neoplasm of lingual tonsil
C02.8	Malignant neoplasm of overlapping sites of tongue
C02.9	Malignant neoplasm of tongue, unspecified
C03.0	Malignant neoplasm of upper gum
C03.1	Malignant neoplasm of lower gum
C03.9	Malignant neoplasm of gum, unspecified
C04.0	Malignant neoplasm of anterior floor of mouth
C04.1	Malignant neoplasm of lateral floor of mouth
C04.8	Malignant neoplasm of overlapping sites of floor of mouth
C04.9	Malignant neoplasm of floor of mouth, unspecified

Title: UM-MP353 Keytruda (pembrolizumab)	Division: Medical Management Department: Utilization Management
Approval Date: 7/22/2025	LOB: QHP, Gold, Goldcare
Effective Date: 7/22/2025	Policy Number: UM-MP353
Review Date: 7/22/2026	Cross Reference Number:
Retired Date:	Page 2 of 23

C05.0	Malignant neoplasm of hard palate
C05.1	Malignant neoplasm of soft palate
C05.2	Malignant neoplasm of uvula
C05.8	Malignant neoplasm of overlapping sites of palate
C05.9	Malignant neoplasm of palate, unspecified
C06.0	Malignant neoplasm of cheek mucosa
C06.1	Malignant neoplasm of vestibule of mouth
C06.2	Malignant neoplasm of retromolar area
C06.80	Malignant neoplasm of overlapping sites of unspecified parts of mouth
C06.89	Malignant neoplasm of overlapping sites of other parts of mouth
C06.9	Malignant neoplasm of mouth, unspecified
C09.0	Malignant neoplasm of tonsillar fossa
C09.1	Malignant neoplasm of tonsillar pillar (anterior) (posterior)
C09.8	Malignant neoplasm of overlapping sites of tonsil
C09.9	Malignant neoplasm of tonsil, unspecified
C10.0	Malignant neoplasm of vallecula
C10.1	Malignant neoplasm of anterior surface of epiglottis
C10.2	Malignant neoplasm of lateral wall of oropharynx
C10.3	Malignant neoplasm of posterior wall of oropharynx
C10.4	Malignant neoplasm of branchial cleft
C10.8	Malignant neoplasm of overlapping sites of oropharynx
C10.9	Malignant neoplasm of oropharynx, unspecified
C12	Malignant neoplasm of pyriform sinus
C13.0	Malignant neoplasm of postcricoid region
C13.1	Malignant neoplasm of aryepiglottic fold, hypopharyngeal aspect
C13.2	Malignant neoplasm of posterior wall of hypopharynx
C13.8	Malignant neoplasm of overlapping sites of hypopharynx
C13.9	Malignant neoplasm of hypopharynx, unspecified
C14.0	Malignant neoplasm of pharynx, unspecified
C14.2	Malignant neoplasm of Waldeyer's ring
C14.8	Malignant neoplasm of overlapping sites of lip, oral cavity and pharynx

Title: UM-MP353 Keytruda (pembrolizumab)	Division: Medical Management Department: Utilization Management
Approval Date: 7/22/2025	LOB: QHP, Gold, Goldcare
Effective Date: 7/22/2025	Policy Number: UM-MP353
Review Date: 7/22/2026	Cross Reference Number:
Retired Date:	Page 2 of 23

C15.3	Malignant neoplasm of upper third of esophagus
C15.4	Malignant neoplasm of middle third of esophagus
C15.5	Malignant neoplasm of lower third of esophagus
C15.8	Malignant neoplasm of overlapping sites of esophagus
C15.9	Malignant neoplasm of esophagus, unspecified
C16.0	Malignant neoplasm of cardia
C16.1	Malignant neoplasm of fundus of stomach
C16.2	Malignant neoplasm of body of stomach
C16.3	Malignant neoplasm of pyloric antrum
C16.4	Malignant neoplasm of pylorus
C16.5	Malignant neoplasm of lesser curvature of stomach, unspecified
C16.6	Malignant neoplasm of greater curvature of stomach, unspecified
C16.8	Malignant neoplasm of overlapping sites of stomach
C16.9	Malignant neoplasm of stomach, unspecified
C17.0	Malignant neoplasm of duodenum
C17.1	Malignant neoplasm of jejunum
C17.2	Malignant neoplasm of ileum
C17.3	Meckel's diverticulum, malignant
C17.8	Malignant neoplasm of overlapping sites of small intestine
C17.9	Malignant neoplasm of small intestine, unspecified
C18.0	Malignant neoplasm of cecum
C18.1	Malignant neoplasm of appendix
C18.2	Malignant neoplasm of ascending colon
C18.3	Malignant neoplasm of hepatic flexure
C18.4	Malignant neoplasm of transverse colon
C18.5	Malignant neoplasm of splenic flexure
C18.6	Malignant neoplasm of descending colon
C18.7	Malignant neoplasm of sigmoid colon
C18.8	Malignant neoplasm of overlapping sites of colon
C18.9	Malignant neoplasm of colon, unspecified
C19	Malignant neoplasm of rectosigmoid junction

Title: UM-MP353 Keytruda (pembrolizumab)	Division: Medical Management Department: Utilization Management
Approval Date: 7/22/2025	LOB: QHP, Gold, Goldcare
Effective Date: 7/22/2025	Policy Number: UM-MP353
Review Date: 7/22/2026	Cross Reference Number:
Retired Date:	Page 2 of 23

C20	Malignant neoplasm of rectum
C21.0	Malignant neoplasm of anus, unspecified
C21.1	Malignant neoplasm of anal canal
C21.2	Malignant neoplasm of cloacogenic zone
C21.8	Malignant neoplasm of overlapping sites of rectum, anus and anal canal
C22.8	Malignant neoplasm of liver, primary, unspecified as to type
C30.0	Malignant neoplasm of nasal cavity
C30.1	Malignant neoplasm of middle ear
C31.0	Malignant neoplasm of maxillary sinus
C31.1	Malignant neoplasm of ethmoidal sinus
C31.2	Malignant neoplasm of frontal sinus
C31.3	Malignant neoplasm of sphenoid sinus
C31.8	Malignant neoplasm of overlapping sites of accessory sinuses
C31.9	Malignant neoplasm of accessory sinus, unspecified
C32.0	Malignant neoplasm of glottis
C32.1	Malignant neoplasm of supraglottis
C32.2	Malignant neoplasm of subglottis
C32.3	Malignant neoplasm of laryngeal cartilage
C32.8	Malignant neoplasm of overlapping sites of larynx
C32.9	Malignant neoplasm of larynx, unspecified
C33	Malignant neoplasm of trachea
C34.00	Malignant neoplasm of unspecified main bronchus
C34.01	Malignant neoplasm of right main bronchus
C34.02	Malignant neoplasm of left main bronchus
C34.10	Malignant neoplasm of upper lobe, unspecified bronchus or lung
C34.11	Malignant neoplasm of upper lobe, right bronchus or lung
C34.12	Malignant neoplasm of upper lobe, left bronchus or lung
C34.2	Malignant neoplasm of middle lobe, bronchus or lung
C34.30	Malignant neoplasm of lower lobe, unspecified bronchus or lung
C34.31	Malignant neoplasm of lower lobe, right bronchus or lung
C34.32	Malignant neoplasm of lower lobe, left bronchus or lung

Title: UM-MP353 Keytruda (pembrolizumab)	Division: Medical Management Department: Utilization Management
Approval Date: 7/22/2025	LOB: QHP, Gold, Goldcare
Effective Date: 7/22/2025	Policy Number: UM-MP353
Review Date: 7/22/2026	Cross Reference Number:
Retired Date:	Page 2 of 23

C34.80	Malignant neoplasm of overlapping sites of unspecified bronchus and lung
C34.81	Malignant neoplasm of overlapping sites of right bronchus and lung
C34.82	Malignant neoplasm of overlapping sites of left bronchus and lung
C34.90	Malignant neoplasm of unspecified part of unspecified bronchus or lung
C34.91	Malignant neoplasm of unspecified part of right bronchus or lung
C34.92	Malignant neoplasm of unspecified part of left bronchus or lung
C43.0	Malignant melanoma of lip
C43.10	Malignant melanoma of unspecified eyelid, including canthus
C43.111	Malignant melanoma of right upper eyelid, including canthus
C43.112	Malignant melanoma of right lower eyelid, including canthus
C43.121	Malignant melanoma of left upper eyelid, including canthus
C43.122	Malignant melanoma of left lower eyelid, including canthus
C43.20	Malignant melanoma of unspecified ear and external auricular canal
C43.21	Malignant melanoma of right ear and external auricular canal
C43.22	Malignant melanoma of left ear and external auricular canal
C43.30	Malignant melanoma of unspecified part of face
C43.31	Malignant melanoma of nose
C43.39	Malignant melanoma of other parts of face
C43.4	Malignant melanoma of scalp and neck
C43.51	Malignant melanoma of anal skin
C43.52	Malignant melanoma of skin of breast
C43.59	Malignant melanoma of other part of trunk
C43.60	Malignant melanoma of unspecified upper limb, including shoulder
C43.61	Malignant melanoma of right upper limb, including shoulder
C43.62	Malignant melanoma of left upper limb, including shoulder
C43.70	Malignant melanoma of unspecified lower limb, including hip
C43.71	Malignant melanoma of right lower limb, including hip
C43.72	Malignant melanoma of left lower limb, including hip
C43.8	Malignant melanoma of overlapping sites of skin
C43.9	Malignant melanoma of skin, unspecified
C44.02	Squamous cell carcinoma of skin of lip

Title: UM-MP353 Keytruda (pembrolizumab)	Division: Medical Management Department: Utilization Management
Approval Date: 7/22/2025	LOB: QHP, Gold, Goldcare
Effective Date: 7/22/2025	Policy Number: UM-MP353
Review Date: 7/22/2026	Cross Reference Number:
Retired Date:	Page 2 of 23

C44.121	Squamous cell carcinoma of skin of unspecified eyelid, including canthus
C44.1221	Squamous cell carcinoma of skin of right upper eyelid, including canthus
C44.1291	Squamous cell carcinoma of skin of left upper eyelid, including canthus
C44.1292	Squamous cell carcinoma of skin of left lower eyelid, including canthus
C44.221	Squamous cell carcinoma of skin of unspecified ear and external auricular canal
C44.222	Squamous cell carcinoma of skin of right ear and external auricular canal
C44.229	Squamous cell carcinoma of skin of left ear and external auricular canal
C44.320	Squamous cell carcinoma of skin of unspecified parts of face
C44.321	Squamous cell carcinoma of skin of nose
C44.329	Squamous cell carcinoma of skin of other parts of face
C44.42	Squamous cell carcinoma of skin of scalp and neck
C44.520	Squamous cell carcinoma of anal skin
C44.521	Squamous cell carcinoma of skin of breast
C44.529	Squamous cell carcinoma of skin of other part of trunk
C44.621	Squamous cell carcinoma of skin of unspecified upper limb, including shoulder
C44.622	Squamous cell carcinoma of skin of right upper limb, including shoulder
C44.629	Squamous cell carcinoma of skin of left upper limb, including shoulder
C44.721	Squamous cell carcinoma of skin of unspecified lower limb, including hip
C44.722	Squamous cell carcinoma of skin of right lower limb, including hip
C44.729	Squamous cell carcinoma of skin of left lower limb, including hip
C44.82	Squamous cell carcinoma of overlapping sites of skin
C44.92	Squamous cell carcinoma of skin, unspecified
C4A.0	Merkel cell carcinoma of lip
C4A.10	Merkel cell carcinoma of unspecified eyelid, including canthus
C4A.111	Merkel cell carcinoma of right upper eyelid, including canthus
C4A.112	Merkel cell carcinoma of right lower eyelid, including canthus
C4A.121	Merkel cell carcinoma of left upper eyelid, including canthus
C4A.122	Merkel cell carcinoma of left lower eyelid, including canthus
C4A.20	Merkel cell carcinoma of unspecified ear and external auricular canal
C4A.21	Merkel cell carcinoma of right ear and external auricular canal
C4A.22	Merkel cell carcinoma of left ear and external auricular canal

Title: UM-MP353 Keytruda (pembrolizumab)	Division: Medical Management Department: Utilization Management
Approval Date: 7/22/2025	LOB: QHP, Gold, Goldcare
Effective Date: 7/22/2025	Policy Number: UM-MP353
Review Date: 7/22/2026	Cross Reference Number:
Retired Date:	Page 2 of 23

C4A.30	Merkel cell carcinoma of unspecified part of face
C4A.31	Merkel cell carcinoma of nose
C4A.39	Merkel cell carcinoma of other parts of face
C4A.4	Merkel cell carcinoma of scalp and neck
C4A.51	Merkel cell carcinoma of anal skin
C4A.52	Merkel cell carcinoma of skin of breast
C4A.59	Merkel cell carcinoma of other part of trunk
C4A.60	Merkel cell carcinoma of unspecified upper limb, including shoulder
C4A.61	Merkel cell carcinoma of right upper limb, including shoulder
C4A.62	Merkel cell carcinoma of left upper limb, including shoulder
C4A.70	Merkel cell carcinoma of unspecified lower limb, including hip
C4A.71	Merkel cell carcinoma of right lower limb, including hip
C4A.72	Merkel cell carcinoma of left lower limb, including hip
C4A.8	Merkel cell carcinoma of overlapping sites
C4A.9	Merkel cell carcinoma, unspecified
C50.011	Malignant neoplasm of nipple and areola, right female breast
C50.012	Malignant neoplasm of nipple and areola, left female breast
C50.019	Malignant neoplasm of nipple and areola, unspecified female breast
C50.021	Malignant neoplasm of nipple and areola, right male breast
C50.022	Malignant neoplasm of nipple and areola, left male breast
C50.029	Malignant neoplasm of nipple and areola, unspecified male breast
C50.111	Malignant neoplasm of central portion of right female breast
C50.112	Malignant neoplasm of central portion of left female breast
C50.119	Malignant neoplasm of central portion of unspecified female breast
C50.121	Malignant neoplasm of central portion of right male breast
C50.122	Malignant neoplasm of central portion of left male breast
C50.129	Malignant neoplasm of central portion of unspecified male breast
C50.211	Malignant neoplasm of upper-inner quadrant of right female breast
C50.212	Malignant neoplasm of upper-inner quadrant of left female breast
C50.219	Malignant neoplasm of upper-inner quadrant of unspecified female breast
C50.221	Malignant neoplasm of upper-inner quadrant of right male breast

Title: UM-MP353 Keytruda (pembrolizumab)	Division: Medical Management Department: Utilization Management
Approval Date: 7/22/2025	LOB: QHP, Gold, Goldcare
Effective Date: 7/22/2025	Policy Number: UM-MP353
Review Date: 7/22/2026	Cross Reference Number:
Retired Date:	Page 2 of 23

C50.222	Malignant neoplasm of upper-inner quadrant of left male breast
C50.229	Malignant neoplasm of upper-inner quadrant of unspecified male breast
C50.311	Malignant neoplasm of lower-inner quadrant of right female breast
C50.312	Malignant neoplasm of lower-inner quadrant of left female breast
C50.319	Malignant neoplasm of lower-inner quadrant of unspecified female breast
C50.321	Malignant neoplasm of lower-inner quadrant of right male breast
C50.322	Malignant neoplasm of lower-inner quadrant of left male breast
C50.329	Malignant neoplasm of lower-inner quadrant of unspecified male breast
C50.411	Malignant neoplasm of upper-outer quadrant of right female breast
C50.412	Malignant neoplasm of upper-outer quadrant of left female breast
C50.419	Malignant neoplasm of upper-outer quadrant of unspecified female breast
C50.421	Malignant neoplasm of upper-outer quadrant of right male breast
C50.422	Malignant neoplasm of upper-outer quadrant of left male breast
C50.429	Malignant neoplasm of upper-outer quadrant of unspecified male breast
C50.511	Malignant neoplasm of lower-outer quadrant of right female breast
C50.512	Malignant neoplasm of lower-outer quadrant of left female breast
C50.519	Malignant neoplasm of lower-outer quadrant of unspecified female breast
C50.521	Malignant neoplasm of lower-outer quadrant of right male breast
C50.522	Malignant neoplasm of lower-outer quadrant of left male breast
C50.529	Malignant neoplasm of lower-outer quadrant of unspecified male breast
C50.611	Malignant neoplasm of axillary tail of right female breast
C50.612	Malignant neoplasm of axillary tail of left female breast
C50.619	Malignant neoplasm of axillary tail of unspecified female breast
C50.621	Malignant neoplasm of axillary tail of right male breast
C50.622	Malignant neoplasm of axillary tail of left male breast
C50.629	Malignant neoplasm of axillary tail of unspecified male breast
C50.811	Malignant neoplasm of overlapping sites of right female breast
C50.812	Malignant neoplasm of overlapping sites of left female breast
C50.819	Malignant neoplasm of overlapping sites of unspecified female breast
C50.821	Malignant neoplasm of overlapping sites of right male breast
C50.822	Malignant neoplasm of overlapping sites of left male breast

Title: UM-MP353 Keytruda (pembrolizumab)	Division: Medical Management Department: Utilization Management
Approval Date: 7/22/2025	LOB: QHP, Gold, Goldcare
Effective Date: 7/22/2025	Policy Number: UM-MP353
Review Date: 7/22/2026	Cross Reference Number:
Retired Date:	Page 2 of 23

C50.829	Malignant neoplasm of overlapping sites of unspecified male breast
C50.911	Malignant neoplasm of unspecified site of right female breast
C50.912	Malignant neoplasm of unspecified site of left female breast
C50.919	Malignant neoplasm of unspecified site of unspecified female breast
C50.921	Malignant neoplasm of unspecified site of right male breast
C50.922	Malignant neoplasm of unspecified site of left male breast
C50.929	Malignant neoplasm of unspecified site of unspecified male breast
C51.0	Malignant neoplasm of labium majus
C51.1	Malignant neoplasm of labium minus
C51.2	Malignant neoplasm of clitoris
C51.8	Malignant neoplasm of overlapping sites of vulva
C51.9	Malignant neoplasm of vulva, unspecified
C53.0	Malignant neoplasm of endocervix
C53.1	Malignant neoplasm of exocervix
C53.8	Malignant neoplasm of overlapping sites of cervix uteri
C53.9	Malignant neoplasm of cervix uteri, unspecified
C54.1	Malignant neoplasm of endometrium
C60.0	Malignant neoplasm of prepuce
C60.1	Malignant neoplasm of glans penis
C60.2	Malignant neoplasm of body of penis
C60.8	Malignant neoplasm of overlapping sites of penis
C60.9	Malignant neoplasm of penis, unspecified
C63.2	Malignant neoplasm of left epididymis
C63.7	Malignant neoplasm of other specified male genital organs
C63.8	Malignant neoplasm of overlapping sites of male genital organs
C64.1	Malignant neoplasm of right kidney, except renal pelvis
C64.2	Malignant neoplasm of left kidney, except renal pelvis
C64.9	Malignant neoplasm of unspecified kidney, except renal pelvis
C65.1	Malignant neoplasm of right renal pelvis
C65.2	Malignant neoplasm of left renal pelvis
C65.9	Malignant neoplasm of unspecified renal pelvis

Title: UM-MP353 Keytruda (pembrolizumab)	Division: Medical Management Department: Utilization Management
Approval Date: 7/22/2025	LOB: QHP, Gold, Goldcare
Effective Date: 7/22/2025	Policy Number: UM-MP353
Review Date: 7/22/2026	Cross Reference Number:
Retired Date:	Page 2 of 23

C66.1	Malignant neoplasm of right ureter
C66.2	Malignant neoplasm of left ureter
C66.9	Malignant neoplasm of unspecified ureter
C67.0	Malignant neoplasm of trigone of bladder
C67.1	Malignant neoplasm of dome of bladder
C67.3	Malignant neoplasm of anterior wall of bladder
C67.4	Malignant neoplasm of posterior wall of bladder
C67.5	Malignant neoplasm of bladder neck
C67.6	Malignant neoplasm of ureteric orifice
C67.8	Malignant neoplasm of overlapping sites of bladder
C67.9	Malignant neoplasm of bladder, unspecified
C68.0	Malignant neoplasm of urethra
C68.8	Malignant neoplasm of overlapping sites of urinary organs
C76.0	Malignant neoplasm of head, face and neck
C81.10	Nodular sclerosis Hodgkin lymphoma, unspecified site
C81.11	Nodular sclerosis Hodgkin lymphoma, lymph nodes of head, face, and neck
C81.12	Nodular sclerosis Hodgkin lymphoma, intrathoracic lymph nodes
C81.13	Nodular sclerosis Hodgkin lymphoma, intra-abdominal lymph nodes
C81.14	Nodular sclerosis Hodgkin lymphoma, lymph nodes of axilla and upper limb
C81.15	Nodular sclerosis Hodgkin lymphoma, lymph nodes of inguinal region and lower limb
C81.16	Nodular sclerosis Hodgkin lymphoma, intrapelvic lymph nodes
C81.17	Nodular sclerosis Hodgkin lymphoma, spleen
C81.18	Nodular sclerosis Hodgkin lymphoma, lymph nodes of multiple sites
C81.19	Nodular sclerosis Hodgkin lymphoma, extranodal and solid organ sites
C81.20	Mixed cellularity Hodgkin lymphoma, unspecified site
C81.21	Mixed cellularity Hodgkin lymphoma, lymph nodes of head, face, and neck
C81.22	Mixed cellularity Hodgkin lymphoma, intrathoracic lymph nodes
C81.23	Mixed cellularity Hodgkin lymphoma, intra-abdominal lymph nodes
C81.24	Mixed cellularity Hodgkin lymphoma, lymph nodes of axilla and upper limb
C81.25	Mixed cellularity Hodgkin lymphoma, lymph nodes of inguinal region and lower limb
C81.26	Mixed cellularity Hodgkin lymphoma, intrapelvic lymph nodes



Title: UM-MP353 Keytruda (pembrolizumab)	Division: Medical Management Department: Utilization Management
Approval Date: 7/22/2025	LOB: QHP, Gold, Goldcare
Effective Date: 7/22/2025	Policy Number: UM-MP353
Review Date: 7/22/2026	Cross Reference Number:
Retired Date:	Page 2 of 23

C81.27	Mixed cellularity Hodgkin lymphoma, spleen
C81.28	Mixed cellularity Hodgkin lymphoma, lymph nodes of multiple sites
C81.29	Mixed cellularity Hodgkin lymphoma, extranodal and solid organ sites
C81.30	Lymphocyte depleted Hodgkin lymphoma, unspecified site
C81.31	Lymphocyte depleted Hodgkin lymphoma, lymph nodes of head, face, and neck
C81.32	Lymphocyte depleted Hodgkin lymphoma, intrathoracic lymph nodes
C81.33	Lymphocyte depleted Hodgkin lymphoma, intra-abdominal lymph nodes
C81.34	Lymphocyte depleted Hodgkin lymphoma, lymph nodes of axilla and upper limb
C81.35	Lymphocyte depleted Hodgkin lymphoma, lymph nodes of inguinal region and lower limb
C81.36	Lymphocyte depleted Hodgkin lymphoma, intrapelvic lymph nodes
C81.37	Lymphocyte depleted Hodgkin lymphoma, spleen
C81.38	Lymphocyte depleted Hodgkin lymphoma, lymph nodes of multiple sites
C81.39	Lymphocyte depleted Hodgkin lymphoma, extranodal and solid organ sites
C81.40	Lymphocyte-rich Hodgkin lymphoma, unspecified site
C81.41	Lymphocyte-rich Hodgkin lymphoma, lymph nodes of head, face, and neck
C81.42	Lymphocyte-rich Hodgkin lymphoma, intrathoracic lymph nodes
C81.43	Lymphocyte-rich Hodgkin lymphoma, intra-abdominal lymph nodes
C81.44	Lymphocyte-rich Hodgkin lymphoma, lymph nodes of axilla and upper limb
C81.45	Lymphocyte-rich Hodgkin lymphoma, lymph nodes of inguinal region and lower limb
C81.46	Lymphocyte-rich Hodgkin lymphoma, intrapelvic lymph nodes
C81.47	Lymphocyte-rich Hodgkin lymphoma, spleen
C81.48	Lymphocyte-rich Hodgkin lymphoma, lymph nodes of multiple sites
C81.49	Lymphocyte-rich Hodgkin lymphoma, extranodal and solid organ sites
C81.70	Other Hodgkin lymphoma, unspecified site
C81.71	Other Hodgkin lymphoma, lymph nodes of head, face, and neck
C81.72	Other Hodgkin lymphoma, intrathoracic lymph nodes
C81.73	Other Hodgkin lymphoma, intra-abdominal lymph nodes
C81.74	Other Hodgkin lymphoma, lymph nodes of axilla and upper limb
C81.75	Other Hodgkin lymphoma, lymph nodes of inguinal region and lower limb
C81.76	Other Hodgkin lymphoma, intrapelvic lymph nodes
C81.77	Other Hodgkin lymphoma, spleen



Title: UM-MP353 Keytruda (pembrolizumab)	Division: Medical Management Department: Utilization Management
Approval Date: 7/22/2025	LOB: QHP, Gold, Goldcare
Effective Date: 7/22/2025	Policy Number: UM-MP353
Review Date: 7/22/2026	Cross Reference Number:
Retired Date:	Page 2 of 23

C81.78	Other Hodgkin lymphoma, lymph nodes of multiple sites
C81.79	Other Hodgkin lymphoma, extranodal and solid organ sites
C85.20	Mediastinal (thymic) large B-cell lymphoma, unspecified site
C85.21	Mediastinal (thymic) large B-cell lymphoma, lymph nodes of head, face, and neck
C85.22	Mediastinal (thymic) large B-cell lymphoma, intrathoracic lymph nodes
C85.23	Mediastinal (thymic) large B-cell lymphoma, intra-abdominal lymph nodes
C85.24	Mediastinal (thymic) large B-cell lymphoma, lymph nodes of axilla and upper limb
C85.25	Mediastinal (thymic) large B-cell lymphoma, lymph nodes of inguinal region and lower limb
C85.26	Mediastinal (thymic) large B-cell lymphoma, intrapelvic lymph nodes
C85.27	Mediastinal (thymic) large B-cell lymphoma, spleen
C85.28	Mediastinal (thymic) large B-cell lymphoma, lymph nodes of multiple sites
C85.29	Mediastinal (thymic) large B-cell lymphoma, extranodal and solid organ sites



Title: UM-MP353 Keytruda (pembrolizumab)	Division: Medical Management Department: Utilization Management
Approval Date: 7/22/2025	LOB: QHP, Gold, Goldcare
Effective Date: 7/22/2025	Policy Number: UM-MP353
Review Date: 7/22/2026	Cross Reference Number:
Retired Date:	Page 2 of 23

7. REFERENCES:

1. Keytruda [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; July 2025.
2. The NCCN Drugs & Biologics Compendium® © 2021 National Comprehensive Cancer aNetwork, Inc. Available at: <http://www.nccn.org>.



Title: UM-MP353 Keytruda (pembrolizumab)	Division: Medical Management Department: Utilization Management
Approval Date: 7/22/2025	LOB: QHP, Gold, Goldcare
Effective Date: 7/22/2025	Policy Number: UM-MP353
Review Date: 7/22/2026	Cross Reference Number:
Retired Date:	Page 2 of 23

REVISION LOG:

REVISIONS	DATE
Creation date	7/22/2025
Annual Review	

Approved:
David Ackman, MD
VP of Medical Director

Approved:
Sanjiv Shah, MD
Chief Medical Officer



Title: UM-MP353 Keytruda (pembrolizumab)	Division: Medical Management Department: Utilization Management
Approval Date: 7/22/2025	LOB: QHP, Gold, Goldcare
Effective Date: 7/22/2025	Policy Number: UM-MP353
Review Date: 7/22/2026	Cross Reference Number:
Retired Date:	Page 2 of 23

Medical Guideline Disclaimer:

Property of Metro Plus Health Plan. All rights reserved. The treating physician or primary care provider must submit MetroPlus Health Plan clinical evidence that the patient meets the criteria for the treatment or surgical procedure. Without this documentation and information, Metroplus Health Plan will not be able to properly review the request for prior authorization. The clinical review criteria expressed in this policy reflects how MetroPlus Health Plan determines whether certain services or supplies are medically necessary. MetroPlus Health Plan established the clinical review criteria based upon a review of currently available clinical information(including clinical outcome studies in the peer-reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). MetroPlus Health Plan expressly reserves the right to revise these conclusions as clinical information changes, and welcomes further relevant information. Each benefit program defines which services are covered. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered and/or paid for by MetroPlus Health Plan, as some programs exclude coverage for services or supplies that MetroPlus Health Plan considers medically necessary. If there is a discrepancy between this guidelines and a member's benefits program, the benefits program will govern. In addition, coverage may be mandated by applicable legal requirements of a state, the Federal Government or the Centers for Medicare & Medicaid Services (CMS) for Medicare and Medicaid members. All coding and website links are accurate at time of publication.

MetroPlus Health Plan has adopted the herein policy in providing management, administrative and other services to our members, related to health benefit plans offered by our organization.